FK506 antigen is a novel macrolide with similar but more potent immunosuppressant activity than cyclosporine. FK506 is used for primary or rescue immunosuppression in patients after solid organ transplantation. Clinically relevant FK506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK 506 blood levels than dosage; therefore therapeutic drug monitoring (TDM) of FK506 levels is a prerequisite for therapy. Whole blood is the matrix of choice for FK506 TDM. The whole blood target level range aimed for in clinical practice is between 3.0 and 20.0 ng/ml and depends on the patient?s liver function, the type of organ transplanted and the time after transplantation.
Applications:
Suitable for use in ELISA. Other applications not tested.
Recommended Dilutions:
ELISA: 1:100-1:2000
Optimal dilutions to be determined by the researcher.
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. FITC conjugates are sensitive to light.
Quick Search
Products 
